Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Augustana College, Rock Island, Illinois.
Transl Res. 2019 Oct;212:14-25. doi: 10.1016/j.trsl.2019.07.003. Epub 2019 Jul 11.
There is a growing need for a more accurate, real-time assessment of tumor status and the probability of metastasis, relapse, or response to treatment. Conventional means of assessment include imaging and tissue biopsies that can be highly invasive, may not provide complete information of the disease's heterogeneity, and not ideal for repeat analysis. Therefore, a less-invasive means of acquiring similar information at greater time points is necessary. Liquid biopsies are samples of a patients' peripheral blood and hold potential of addressing these criteria. Ongoing research has revealed that a tumor can release circulating cells, genetic materials (DNA or RNA), and exosomes into circulation. These potential biomarkers can be captured in a liquid biopsy and analyzed to determine disease status. To achieve these goals, numerous technologies have been developed. In this review, we discuss both prominent and newly developed technologies for circulating tumor cell capture and analysis and their clinical impact.
目前，人们越来越需要一种更精确、实时的肿瘤状态评估方法，以及转移、复发或对治疗反应的可能性评估方法。传统的评估方法包括影像学和组织活检，但这些方法具有很强的侵入性，可能无法提供疾病异质性的完整信息，也不适合重复分析。因此，需要一种侵入性更小的方法来在更多时间点获取类似的信息。液体活检是患者外周血样本的一种，具有满足这些标准的潜力。目前的研究表明，肿瘤可以将循环细胞、遗传物质（DNA 或 RNA）和外泌体释放到循环中。这些潜在的生物标志物可以在液体活检中被捕获并进行分析，以确定疾病状态。为了实现这些目标，已经开发了许多技术。在这篇综述中，我们讨论了循环肿瘤细胞捕获和分析的突出技术和新兴技术，以及它们的临床影响。
